KRAS and neoplasm: However, the benefit of using antiangiogenic drugs beyond progression regarding OS was weaker in the subgroup of women (n = 1,047) with a HR of 0.81 (95%-CI, 0.70–0.94) and absent in patients bearing a tumor with KRAS mutation (n = 1,260) with a HR of 0.89; 95%-CI, 0.78–1.02.